Aspira Pathlab P/E Ratio
Current P/E Ratio
39.96
High Valuation
Very High - High growth expectations or significantly overvalued
Aspira Pathlab (ASPIRA) P/E ratio is 39.96 (High), EPS (TTM) ₹1.97, current price ₹107.65 on BSE — Very High - High growth expectations or significantly overvalued. Read Aspira Pathlab dividend payments for the complete payout history and dividend yield track record.
Current Valuation Metrics
P/E Ratio
39.96
Current Price
₹107.65
EPS (TTM)
₹1.97
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
112.63
Sector Median
41.37
Sector Rank
#11 of 57
Sector Percentile
19.3%
Earnings Breakdown (TTM)
TTM EPS
₹1.54
Mar 2025
₹0.66
Jun 2025
₹0.41
ASPIRA P/E Ratio — Valuation Signal & Historical Context
Aspira Pathlab P/E 39.96 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see Aspira Pathlab share price screener.
- Stock appears overvalued with PE of 39.96, suggesting caution for new investments
- Trading at discount to sector average PE of 112.63
ASPIRA vs Healthcare Services Peers — P/E Ratio Comparison
Aspira Pathlab P/E 39.96 vs Healthcare Services average 112.63, median 41.37 — range 8.87–3045.0.
Sector Average
112.63
Sector Median
41.37
Lowest P/E
8.87
Highest P/E
3045.0
Companies
57
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Star Imaging And Path Lab | STARIMAGIN | 8.87 | ₹165 | Low |
| Abate AS Industries | ABATEAS | 12.29 | ₹153 | Low |
| Nidan Labs & Healthcare | NIDAN | 12.5 | ₹18 | Low |
| Deccan Health Care | DECCAN | 12.92 | ₹31 | Low |
| Shanmuga Hospital | SHANMUGA | 14.28 | ₹59 | Low |
| Krsnaa Diagnostics | KRSNAA | 17.41 | ₹1,792 | Moderate |
| Sangani Hospitals | SANGANI | 17.61 | ₹59 | Moderate |
| One Global Service Provi… | ONEGLOBAL | 17.64 | ₹1,178 | Moderate |
| Invicta Diagnostic | INVICTA | 17.85 | ₹85 | Moderate |
| 3B BlackBio DX | 3BBLACKBIO | 17.9 | ₹1,088 | Moderate |